Overview

A Study of LY3437943 in Participants With Type 2 Diabetes

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide